ATB 200

Drug Profile

ATB 200

Alternative Names: AT-B200/AT2220; ATB 200+chaperone; ATB 200/AT 2221; ATB-200; ATB200+AT2221; rhGAA-Amicus Therapeutics

Latest Information Update: 21 Feb 2017

Price : $50

At a glance

  • Originator Amicus Therapeutics
  • Class Alpha-glucosidases; Enzymes
  • Mechanism of Action Alpha glucosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glycogen storage disease type II

Most Recent Events

  • 15 Feb 2017 Pharmacodynamic results from a preclinical trial in Glycogen storage disease type II released by Amicus Therapeutics
  • 09 Jan 2017 Adverse events data from a phase I/II trial in Glycogen storage disease type II released by Amicus Therapeutics
  • 09 Dec 2016 Interim adverse event, pharmacokinetics and pharmacodynamic data from a phase I/II trial in Glycogen storage disease type II released by Amicus Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top